top of page

Price reduction paves the way for expanded access to highly effective MDR-TB

resisttb

Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.

27 views0 comments

Recent Posts

See All

Armand Van Deun Scholarship Initiative

The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...

Comments


bottom of page